SAN MATEO, Calif., June 1, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON - News) announced enrollment and dosing of the first patient in the Phase 3 confirmatory study of Marqibo(R) (vincristine sulfate liposome injection) in adults (60 years of age and older) with newly diagnosed Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL), known as the HALLMARQ Study.
